Copyright: ©Author(s) 2026.
World J Nephrol. Jun 25, 2026; 15(2): 109420
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.109420
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.109420
Table 1 Baseline characteristics of Fabry disease patients
| Patient ID | Age | Sex | Hypertension | Proteinuria (g/24 hours) | eGFR (mL/minute) | Extra-renal manifestations |
| A.1 | 29 | Male | Yes | 5.5 | 23.7 | Angiokeratoma, LVH, acroparesthesia, deafness |
| B.1 | 20 | Male | Yes | 2.6 | 75.1 | Angiokeratoma, seizure, LVH |
| B.2 | 22 | Male | No | 2.8 | 77.4 | None |
| C.1 | 25 | Male | No | 1.3 | 127 | Angiokeratoma, anhidrosis, acroparesthesia |
| C.2 | 23 | Male | No | Negative | 130 | None |
| C.3 | 16 | Female | No | Negative | 135 | None |
Table 2 Renal function trajectory and treatment response
| Patient ID | ERT start age | Baseline eGFR (mL/minute/1.73 m2) | eGFR after 2 years | Proteinuria trend | Outcome |
| A.1 | Not initiated | 23.7 | ESRD (year 1) | Increased | Dialysis |
| B.1 | 20 | 75.1 | 38 (year 9) | Stable, then ↑ | ESRD |
| B.2 | 22 | 77.4 | 76 (year 4) | ↓ | Stable |
| C.1 | 25 | 127 | 122 (year 2) | Stable | Stable |
| C.2 | 23 | 135 | 130 (year 3) | None | Stable |
| C.3 | 16 | 128 | 128 (year 2) | None | Stable |
- Citation: Tlili S, Ghabi H, Mami I, Ben Hmida F, Rais L, Zouaghi MK. Renal involvement in Fabry disease from Tunisian families: Six case reports. World J Nephrol 2026; 15(2): 109420
- URL: https://www.wjgnet.com/2220-6124/full/v15/i2/109420.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i2.109420